Mika’s Post

#artificialintelligence in #medicine and #research: This was the topic of an event organised by the Bayerische Akademie der Wissenschaften in collaboration with the Süddeutsche Zeitung. The stream of the event is now available #online, watch presentations on the responsible use of #medicaldata, on the successes already achieved through #dataanalysis in the fight against #cancer, #leukaemia and other #diseases: https://lnkd.in/dncfekcT (in German) #health, #digitalisation, #IT4Science, #bigdata, #healthdata, #usecases, #success, Nerdpol - Redaktionsbüro für Medizin- und Wissenschaftsjournalismus, 1E9, EuroCC GCS, Data & Analytics, Data & Analytics News

Our project 'Artificial Intelligence for treating Cancer Therapy Resistance (AI-Care)' has just been awarded 5 million Euros over the next 6 years by the Carl Zeiss Foundation (CZS) as part of the #CZS #Breakthroughs research program. The team behind the project consists of #RPTU, #DKFZ and the University of Heidelberg. Glioblastomas are aggressive brain tumors characterized by a high degree of phenotypic heterogeneity and #plasticity. Their ability to switch to resistant cell states renders conventional therapies ineffective. The goal of this project is to decipher the cancer plasticity code of #glioblastoma using state-of-the-art #AI and optimization techniques that characterize the drug response dynamics of glioblastoma. Our research aims for breakthroughs in understanding the biological basis of cancer plasticity and the development of #personalized therapeutic #treatments. The project team's work has the potential to break new ground not only in the treatment of glioblastoma, but also in the treatment of other deadly cancers. The concept of AI-based personalized precision medicine may become a reality in the medium term. #AIinHealth #CancerTreatment #PersonalisedTherapy #Glioblastoma #CZS

𝐃𝐨 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐰𝐡𝐚𝐭 𝐢𝐬 𝐭𝐫𝐢𝐜𝐤𝐲 𝐢𝐧 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐧𝐠 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬?💓   In medical practice, getting an accurate diagnosis is super important but poses a big challenge. It's like the starting point for deciding what to do next. But here's the thing: doctors often have to deal with probabilities instead of certainties, which can be tricky.   🩺 𝐁𝐚𝐲𝐞𝐬' 𝐓𝐡𝐞𝐨𝐫𝐞𝐦 is a mathematical concept that helps doctors guide clinical decision-making, after a test result is available. It explains, why a 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑡𝑒𝑠𝑡 𝑟𝑒𝑠𝑢𝑙𝑡 is more likely to be accurate (true positive) when found in a group with a high disease prevalence. Conversely, in a group with a low disease prevalence, it's prone to be a false alarm (false positive). 📈 𝐋𝐞𝐭'𝐬 𝐚𝐭𝐭𝐞𝐦𝐩𝐭 𝐭𝐨 𝐠𝐫𝐚𝐬𝐩 𝐭𝐡𝐢𝐬 𝐜𝐨𝐧𝐜𝐞𝐩𝐭 𝐰𝐢𝐭𝐡 𝐚 𝐬𝐢𝐦𝐩𝐥𝐞 𝐚𝐧𝐚𝐥𝐨𝐠𝐲: Picture you spot a bald man randomly on the street, and your mind wanders about his probability of having cancer. What would your initial guess be? Now, the scenario shifts, and you find yourself in a hospital, encountering the same bald man. When you see a bald man in a hospital setting, your intuition tends to incline toward a higher probability, doesn't it? 😉   This highlights the importance of considering pre-test probabilities when interpreting medical test results.   Discover in this article published by Dr. Thomas M. Helms, Prof. Christian A. Perings und Prof. B. Andrew Remppis in Cardio News, why accurately assessing the pre-test probability is crucial in diagnosing coronary artery disease (#CAD) and how 𝐂𝐚𝐫𝐝𝐢𝐨 𝐄𝐱𝐩𝐥𝐨𝐫𝐞𝐫®improves the patient journey. https://lnkd.in/eGtZ5iGd Exploris Health AG offers through Cardio Explorer® the only precise, simple, and reliable diagnostic test, that can improve the diagnostic pathway through precise assessment of the pre-test probability, ensuring patients at risk are identified early, while at the same time ensuring the reduction of false positive results and avoiding unnecessary and costly procedures.   🚀💓 #Innovation #Heart 📚💡 #AI #Startups #MedicalScience

Our latest paper showing the clinical implications of suspending and altering cardiac rehabilitation programs during the COVID-19 pandemic!

Paris is not the destination for tourism and fashion only - it has become "the destination" of health technology start-up companies too. Launched by President Emmanuel Macron, the Healthcare Innovation Plan aiming to make France a global health-care innovation leader by 2030 is giving a boost to the sector. The number of health-technology companies in France is growing - one fourth of these companies are based in Paris. The innovative solutions by the French start-ups like Resolve Stroke (bedside neuromonitoring device to monitor patients recovering from strokes and traumatic brain injuries), DNA Script (world’s first DNA printers), Owkin (medical artificial-intelligence company) are revolutionizing global healthcare. PariSanté Campus Vincent Hingot Thomas Ybert Jean-Philippe Vert

Last week saw the second Anthropy conference convene at the Eden Project to inspire a better Britain. I had the privilege of jointing Adelphi Group for a panel discussion on the role of prevention in healthcare alongside  Sophie Castell, Dr Sebastian Vaughan, Stuart Cooper and Helen McDowell. It was hugely inspirational to hear about the great benefits myeloma patients could gain from preventative interventions, how ViiV is making their essential products available in countries with poor access to preventative medicines and from Sebastian about the potential role of overlooked botanticals. With the rapid evolution of the use cases for AI driven tech we have a huge opportunity to scale primary prevention interventions and prevention of disease progression in a way impossible previously. In the spirt of optimism of Anthropy it has been so exciting that within just a week of the conference we have had a flow of announcement on preventative healthcare for example: -         NICE approval for next generation tech to help Type 1 Diabetes patients more easily and accurately manage their blood glucose brings the hope of preventing or delaying onsetting complications of diabetes -         The hunt has started for a blood test to enable the early detection of Alzheimer’s which is an essential step for finding early interventions slow disease progression -         The first baby in Northern Ireland has been born who will not have paper based health records, immediately this offers opportunities in patient safety but digitalisation has huge future potential as we learn more about how to identify early risks -         Advances in rapid diagnostics of tumours AI won’t be a silver bullet but if we can work out how to manage quality control in a way that doesn’t smother innovation, work out how to put more value on investment in prevention rather than cure and most crucially ensure that solutions are designed with patients then the picture of prevention could look quite different by Anthropy 3.

🚀 Breaking: Medotrax is proud to announce its collaboration with the Davos Alzheimer's Collaborative (DAC) on the #AccurateDiagnosis project a cutting-edge initiative to enhance the diagnosis of Dementia. 🧠   🔬 In this project, we are deploying our newly developed digital cognitive tests and questionnaires, aiming for quicker and better diagnosis of Dementia in combination with blood-based biomarkers (BBMs) and confirmatory diagnostic testing.   🌍 Led by the Davos Alzheimer’s Collaborative (DAC) Healthcare System Preparedness team, the #AccurateDiagnosis project is the first-ever global implementation research program studying the use of BBMs in the diagnostic process.   🏥 Healthcare systems across Germany, Japan, the Netherlands, the U.K., and the U.S. will:   • Deploy • Evaluate • Disseminate real-world learnings of BBMs and confirmatory #Alzheimers pathology testing   🎯 This initiative aims to enable healthcare providers to transition these validated research tools into everyday clinical practice, accelerating timely patient care.   🔗 Click here to read more about the DAC Accurate Diagnosis project: https://lnkd.in/ehgpvcpG 📖 To learn more about Medotrax and our innovative solutions, visit our website: medotrax.com   #Dementia #Alzheimers #HealthcareInnovation #MedicalResearch #Medotrax #DigitalHealth #DavosAlzheimersCollaborative

GE Health says it plans to develop an AI-assisted ultrasound imaging tool (https://lnkd.in/eguDQKh5) that is so easy to use, that even healthcare providers without specialized training will be able to operate it. The device's research and development will be funded by a $44 million grant from the Bill & Melinda Gates Foundation, which has historically invested (https://lnkd.in/gDaR2A6x) in the roll-out of new technologies in resource-poor settings to address gaps in healthcare access.GE says the AI-powered (https://lnkd.in/g-k24jK) imaging technology has been designed to be dispersed to low-and-middle income countries where the services of healthcare providers may be stretched thin. The ultrasound tool will be more effective at providing clear readings of lung and ultrasound scans across maternal and fetal care as well as pediatric lung health. GE is working on AI-powered ultrasounds to combat pediatric and maternal mortality rates

#empirica-projects-series: In this series, we introduce you to our ongoing projects. Today: SMASH-HCM 🫀 The aim of the project is to revolutionise the stratification, management, and guidance of Hypertrophic Cardiomyopathy (HCM) patients using Hybrid Digital Twin Solutions. HCM, the most common inherited heart disease, poses significant risks, especially for young athletes. Key Highlights: 🔍 Diversity in Phenotypes: Multiple causal mutations and variations in cellular processes result in diverse phenotypes and disease progression. However, the current diagnosis treats HCM as a single disease, leading to suboptimal care. 🌐 Collaborative Approach: SMASH-HCM unites 8 research partners, 3 hospitals, 3 SMEs, and a global health-technology corporation, collaborating with patients. This consortium will develop a digital-twin platform integrating dynamic biophysical models and data-driven approaches. 💡 Innovation in Digital Twins: From in-vitro tools to in-silico molecular to systemic level models, SMASH-HCM integrates various technologies, including explainable artificial intelligence. The goal is to offer a decision support solution for both healthcare professionals and patients. 📈 Our Role (Exploitation, Dissemination, and Communication): Our objectives include stakeholder engagement, effective result dissemination, and the development of exploitation, sustainability, and IP management plans. Specific tasks involve cost-effectiveness analysis, scalable impact modeling, identifying financial implications, determining commercially exploitable assets with business planning, and supporting communication dynamics. Empirica aims to amplify the success of SMASH-HCM, ensuring widespread impact and sustainability. 🌍 Impact and Future Prospects: SMASH-HCM aims to deliver new insights into HCM, improved patient care, and a validated stratification and management strategy. The project also paves the way for future digital-twin platforms for various cardiac diseases, integrating models and data from different scales and sources. 🎯 Towards a Better Future: SMASH-HCM not only promises a cost-efficient and effective solution for HCM but also serves as a model for innovation in healthcare. Stay tuned for updates on this game-changing project! #SMASHHCM #HealthcareInnovation #DigitalTwins #CardiologyResearch #PatientCare Tampere University  Politecnico di Milano  University of Bologna (Alma Mater Studiorum – Università di Bologna)  Università degli Studi di Firenze  Azienda Ospedaliero-Universitaria Careggi Universitätsklinikum Hamburg Eppendorf  University College Dublin Université de Rennes  INSERM Institut national de la santé et de la recherche médicale  CHU de Rennes Medtronic Bakken Research Center BV  InSilicoTrials  The Chancellor Masters & Scholars of The University of Oxford  Pharmatics

🌟 Interesting development 🌟 Researchers from our partner, The Netherlands Cancer Institute, successfully developed a new method to detect the correct T-cells on a large scale. The Cell and Gene Therapy workstream within the Oncode Accelerator program amongst others focuses on immunotherapy in which the patients' T-cells are trained to attack the tumour. Therefore, this new method can be of interest for the development of new immunotherapies. Read the whole article via the link below 👇 https://lnkd.in/dtTcg2kb